Kayla Bey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kayla Bey has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alex Rock
Massachusetts General Hospital
1 shared publication - Eric Gillett
Department of Pharmacy, Brigham and Women's Hospital , Boston, Massachusetts
1 shared publication - Jeffrey C. Pearson
Department of Pharmacy, Brigham and Women's Hospital , Boston, Massachusetts
1 shared publication - Joshua Mercure
Department of Pharmacy, Massachusetts General Hospital , Boston, Massachusetts 02114
1 shared publication Suzanne M McCluskey
Division of Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts
1 shared publication
Latest Publications
- Open Access
- 24 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10)
Evaluating the Efficacy of Crushed Bictegravir/Emtricitabine/Tenofovir Alafenamide Administered via Tube
Human immunodeficiency virus (HIV) viral suppression was evaluated after receipt of crushed or dissolved bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) administered via enteral tube during hospitalization. Eighty-nine percent of patients (17/19) were virally suppressed (<200 copies/mL) within 1 year of receiving B/F/TAF via tube, suggesting that administration via tube is a reasonable alternative to changing antiretroviral regimens.
- 24 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10)
Open AccessEvaluating the Efficacy of Crushed Bictegravir/Emtricitabine/Tenofovir Alafenamide Administered via Tube
Human immunodeficiency virus (HIV) viral suppression was evaluated after receipt of crushed or dissolved bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) administered via enteral tube during hospitalization. Eighty-nine percent of patients (17/19) were virally suppressed (<200 copies/mL) within 1 year of receiving B/F/TAF via tube, suggesting that administration via tube is a reasonable alternative to changing antiretroviral regimens.